Approved by the FDA in July 2021 and launched in China in June 2022, finerenone has demonstrated significant clinical benefits in reducing kidney function decline, kidney failure, cardiovascular death, and non-fatal heart attacks . The (S)-enantiomer is the active pharmaceutical ingredient, and recent synthetic advances have enabled efficient, scalable production via late-stage asymmetric transfer hydrogenation and resolution methods .
We offer the full series of finerenone key intermediates and impurity reference standards to support your research, development, and manufacturing programs.
|
Parameter |
Specification |
|
Product Name |
Finerenone (BAY 94-8862) |
|
CAS Number |
1050477-31-0 |
|
Molecular Formula |
C₂₁H₂₂N₄O₃ |
|
Molecular Weight |
378.43 g/mol |
|
Appearance |
White to off-white crystalline powder |
|
Storage Condition |
2–8 °C, protected from light and moisture |
Cosperpharm offers the complete range of finerenone intermediates and related impurities:
First-in-Class Mineralocorticoid Receptor Antagonist
Finerenone is a non-steroidal MRA with superior selectivity and safety profile compared to steroidal MRAs. Approved for chronic kidney disease with type 2 diabetes, it represents a major therapeutic advance with blockbuster market potential .
Optimized Convergent Synthetic Routes
Recent synthetic innovations have achieved scalable, chromatography-free production via Hantzsch cyclization with 2-cyanoethyl acetoacetate (CAS 65193-87-5) as the optimal surrogate, delivering key 1,4-DHP intermediates in up to 88% yield . Chiral resolution using (+)-dibenzoyl-D-tartaric acid enables efficient access to the (S)-enantiomer without chromatography .
Full Intermediate Supply Chain
Cosperpharm supplies the complete cascade of finerenone intermediates—from the aromatic nitrile building block (CAS 21962-45-8) through the advanced 1,4-DHP core (CAS 1050477-39-8) and the resolved chiral acid (CAS 1050477-45-6). This enables flexible route development and risk mitigation.
High-Purity Impurity Reference Standards
Our impurity portfolio includes fully characterized Finerenone Impurity 17 (CAS 1050477-39-8) and Impurity 13 (CAS 1050477-45-6) with comprehensive analytical data to support method validation and regulatory submissions.
Cosperpharm supplies Finerenone API, the full series of key intermediates, and impurity reference standards with rigorous quality control and comprehensive documentation.
Whether you need R&D quantities for process development, reference standards for method validation, or bulk intermediates for commercial manufacturing, we deliver consistent quality with full batch traceability. Contact us today for a quote or to discuss your requirements.
